The global phenylketonuria market size was valued at USD 1.32 billion in 2025 and is projected to grow from USD 1.40 billion in 2026 to USD 2.29 billion by 2034, registering a CAGR of 6.3% during the forecast period from 2026 to 2034. North America dominated the phenylketonuria market with a market share of 38.5% in 2025.
Phenylketonuria (PKU) is a rare, inherited metabolic disorder that prevents phenylalanine breakdown. PAH gene mutations cause PKU by directing phenylalanine hydroxylase production. This enzyme degrades phenylalanine, an essential amino acid found in many foods. Deficiency or non-functioning PAH causes phenylalanine accumulation and serious health issues. PKU patients without early diagnosis and treatment can develop intellectual disability, seizures, behavioral issues, and mental disorders due to phenylalanine buildup.
A musty smell in the breath, skin, or urine and lighter skin, hair, and eyes than family members are other symptoms. PKU treatment involves a lifelong low-phenylalanine diet and specialized supplements for nutrition. Sometimes, sapropterin dihydrochloride can help manage phenylalanine levels. PKU patients can live healthy, normal lives with early diagnosis, diet, and treatment. However, untreated, the condition can have serious and irreversible consequences, emphasizing the need for newborn screening and intervention.
Download a Free Sample To learn more about this report,
Sepiapterin Is Expanding Oral Treatment Options for Phenylketonuria
The need for effective therapies that lower phenylalanine levels is supporting the adoption of oral pharmacological treatments for eligible PKU patients. The FDA approved SEPHIENCE (sepiapterin) in July 2025 for adults and children aged 1 month and older with sepiapterin-responsive PKU, with the treatment taken once daily as an oral powder. In the Phase 3 APHENITY trial, sepiapterin reduced blood phenylalanine by 63% after six weeks, compared with 1% with placebo, expanding oral treatment options for PKU management.
Pharmacological Therapies Are Reducing Dependence on Strict Phenylalanine-Restricted Diets
The challenges of maintaining strict lifelong phenylalanine restriction are increasing interest in pharmacological therapies that can improve blood phenylalanine control and allow greater dietary flexibility. Interim Phase 3 data from the APHENITY extension study showed that mean dietary phenylalanine intake among 102 assessed participants increased from 27.6 to 62.5 mg/kg/day after 26 weeks of sepiapterin treatment. This transition toward diet liberalization can reduce the nutritional burden of PKU management while supporting greater flexibility in everyday food choices.
Improved Newborn Screening and PKU Management Awareness Are Increasing Treatment Demand, Which Drives the Market.
Improved newborn screening increases the identification of infants with phenylketonuria soon after birth, creating demand for early diagnosis and long-term disease management. Earlier identification allows healthcare providers to begin dietary management and appropriate treatment before elevated phenylalanine levels cause serious complications. The outcome is a larger diagnosed patient pool and sustained demand for diagnostic tests, specialized nutritional products, and PKU therapies. For example, newborn blood-spot screening programs can identify PKU within the first days of life and enable timely referral to metabolic care specialists.
Greater awareness of lifelong PKU management increases demand for regular monitoring, specialized nutrition, and appropriate treatment among patients and caregivers. Better understanding of the need for continued phenylalanine control supports consistent use of disease-management products and healthcare services. The outcome is sustained demand for PKU therapies, metabolic monitoring, and specialized low-phenylalanine nutritional products. For example, patient education programs can help families maintain regular blood testing and dietary management throughout childhood and adulthood.
High Costs of PKU Treatment and Specialized Therapies and Limited Access to Diagnosis and Care Restrain Market Expansion.
High treatment costs can make PKU management less affordable, particularly for patients requiring specialized therapies and lifelong nutritional products. Expensive medicines, medical foods, monitoring, and regular clinical care can increase the financial burden on patients and healthcare systems. These affordability barriers can reduce treatment uptake and limit broader market expansion.
Limited access to specialized PKU diagnosis and care can restrict timely identification and management of patients, particularly in underserved regions. Gaps in newborn screening, metabolic testing, specialist availability, and dedicated treatment centers can delay diagnosis and access to appropriate therapies. These healthcare access limitations can reduce treatment adoption and slow market growth.
Telehealth Services and Genetic Testing Are Expanding PKU Care and Risk Assessment, Which Offers Growth Opportunities.
PKU patients, caregivers, metabolic clinics, and healthcare providers can use telehealth for remote consultations, dietary guidance, and ongoing specialist support. Wider virtual access creates revenue through teleconsultation fees, digital care platforms, remote monitoring, and subscription-based services. Companies such as Teladoc Health provide platforms that support remote healthcare delivery.
Patients, families, genetic counselors, and specialized healthcare providers can use genetic testing to identify PAH gene variants and support PKU risk assessment. Greater testing adoption creates revenue through genetic test kits, laboratory services, interpretation, and counseling. Companies such as Invitae and Labcorp offer genetic testing services.
Limited Treatment Response, Treatment Discontinuation, and Side-Effect Management Hinder Market Growth.
PKU therapies do not provide the same response across all patients because treatment effectiveness can depend on disease severity and genetic characteristics. The FDA notes that only a subset of patients are candidates for sapropterin, while pegvaliase has age and safety-related limitations, restricting the addressable patient population for individual therapies.
Adverse effects and the burden of long-term therapy can lead some patients to discontinue treatment, reducing persistence and limiting real-world uptake. A recent multicenter study of adolescents receiving pegvaliase reported a 24.5% discontinuation rate, with higher discontinuation during major school-to-college transition periods.
The enzyme replacement therapy segment dominated the market with a market share of 31.6% in 2025. Enzyme replacement therapy is commonly used to replace or supplement deficient enzymes in patients with inherited metabolic disorders. Its use can help manage disease-related symptoms and support the treatment of conditions caused by specific enzyme deficiencies. The medication segment, dietary therapy segment, and gene therapy segment also contribute to treatment by addressing symptoms, nutritional requirements, or underlying genetic causes.
The gene therapy segment is expected to grow at the fastest CAGR of 16.4% during the forecast period 2026–2034. Gene therapy focuses on addressing genetic abnormalities by introducing, modifying, or replacing genetic material associated with a disease. Advances in genetic medicine and research into rare inherited disorders are supporting continued development of gene-based treatment approaches. The enzyme replacement therapy segment, medication segment, phenylketonuria Market, and dietary therapy segment, phenylketonuria Market remain important approaches for managing metabolic and inherited conditions.
Request Customizationto receive a tailored report.
The newborn screening segment dominated the market with a market share of 46.5% in 2025. Newborn screening helps identify certain inherited and metabolic disorders at an early stage, often before significant symptoms become apparent. Early identification can support timely clinical evaluation and treatment, which is particularly important for disorders where early intervention may help manage disease progression. The genetic testing segment and biochemical testing segment also support diagnosis by identifying genetic abnormalities or changes in biochemical markers.
The genetic testing segment is expected to grow at the fastest CAGR of 11.3% during the forecast period 2026–2034. Genetic testing can help identify disease-causing genetic variants and support diagnosis of inherited disorders. Increasing use of molecular diagnostic techniques and greater understanding of genetic diseases are contributing to the adoption of genetic testing. The newborn screening segment and biochemical testing segment also remain important for early detection and clinical assessment.
The hospitals segment dominated the market with a market share of 35.5% in 2025. Hospitals provide comprehensive diagnostic and treatment facilities for patients with complex inherited and metabolic disorders. They can support multidisciplinary care involving physicians, laboratory specialists, genetic counselors, and other healthcare professionals. The specialty clinics segment, home healthcare segment, and research institutes segment, phenylketonuria Market also contribute to patient management, specialized care, and disease research.
The research institutes segment is expected to grow at the fastest CAGR of 12.8% during the forecast period 2026–2034. Research institutes play an important role in studying disease mechanisms, developing new diagnostic approaches, and advancing therapies for rare and inherited disorders. Ongoing research into genetic medicine and disease-specific treatment approaches can support demand for specialized research capabilities. The hospitals segment, specialty clinics segment, and home healthcare segment also remain relevant across diagnosis, treatment, and long-term disease management.
Speak to an Analystto discuss market opportunities.
North America phenylketonuria market held the dominant position, accounting for a 38.5% share in 2025. The region benefits from established healthcare infrastructure, advanced diagnostic capabilities, and growing access to specialized treatment for phenylketonuria. U.S. phenylketonuria market is supported by continued population aging, with the share of people aged 65 and over projected to increase from 18.9% in 2025 to 23.4% by 2060, according to the U.S. Census Bureau.
Canada phenylketonuria market is supported by an aging population, with Statistics Canada projecting the share of people aged 65 and over to increase from 19.5% in 2025 to between 22.6% and 32.5% by 2075 across different projection scenarios.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe phenylketonuria market is projected to register the fastest CAGR of 12.1% during the forecast period, supported by improved newborn screening programs, increasing disease awareness, and expanding access to specialized therapies. U.K. phenylketonuria market is supported by demographic aging, with people aged 65 and over projected to account for 23.6% of the population by 2035, according to the Office for National Statistics.
Germany phenylketonuria market is expected to see increasing healthcare needs among older adults, with Germany’s Federal Statistical Office projecting that one in four people will be aged 67 or over by 2035, compared with one in five in 2024. France phenylketonuria market is supported by population aging, with INSEE projecting 49 people aged 65 or over for every 100 people aged 20–64 by 2040, compared with 40 per 100 in 2026.
Asia Pacific phenylketonuria market accounted for a 20.6% share in 2025 and is projected to grow at a CAGR of 11.5%, driven by improving healthcare infrastructure, rising awareness of inherited metabolic disorders, and increasing adoption of early diagnosis and treatment. Japan phenylketonuria market is expected to face increasing healthcare needs associated with population aging, as Japan’s Ministry of Health, Labour and Welfare projects that people aged 65 and over will represent about 35% of the population by 2040.
China phenylketonuria market is supported by a rapidly aging population, with official projections indicating that the number of people aged 60 and over will exceed 400 million and account for more than 30% of the population by around 2035. India phenylketonuria market is supported by a rapidly expanding older population, with UNFPA projecting that 346 million people aged 60 and over will live in India by 2050, representing nearly 21% of the population.
The Phenylketonuria Market is moderately fragmented, with competition comprising pharmaceutical companies, biotechnology firms, specialized rare-disease drug developers, medical nutrition providers, and companies developing enzyme-based and metabolic therapies. The leading players in the Phenylketonuria Market are BioMarin Pharmaceutical Inc., Nutricia, Vitaflo, Cambrooke Therapeutics, and Abbott Laboratories; a reliable cumulative market-share percentage specifically for these five companies is not publicly disclosed, so no unsupported figure is assigned to their combined global market share.
Established players compete through approved treatment portfolios, clinical evidence, regulatory expertise, manufacturing capabilities, patient-support programs, and established relationships with healthcare providers and specialty centers. Emerging players in the phenylketonuria market ecosystem compete through novel mechanisms of action, improved treatment convenience, broader patient eligibility, targeted therapies, and innovative approaches to phenylalanine management. Competitive differentiation also depends on treatment efficacy, safety, dosing convenience, long-term disease management, and the ability to address unmet needs across different patient groups. The FDA's 2025 approval of sepiapterin and 2026 expanded approval of pegvaliase illustrate continued development and expansion of pharmacological treatment options for PKU.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Ovarian Cancer Market Size, Share, Growth, Analysis, Report, 2034
Tulathromycin Market Size, Share, Growth, Analysis, Report, 2034
Renal Replacement Therapy Market Size, Share, Growth, 2034
Advanced Cancer Pain Management Market Size, Share, 2034
Facial Injectable Market Size, Share, Growth, Forecast, 2034
Trigeminal Neuralgia (TN) Treatment Market Size, Share, 2034
We are featured on:
sales@straitsresearch.com